Login to Your Account

Up-front costs higher

Single-source manufacturing faster, cheaper in long run

By Brian Orelli
Staff Writer

Monday, November 13, 2017

The old saying "many hands make quick work" doesn't apply to drug manufacturing for use in clinical trials, according to a new study from The Tufts Center for the Study of Drug Development (CSDD) looking at single-source vs. multivendor manufacturing at contract development and manufacturing organizations (CDMOs).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription